$0.23
-0.01(-4.21%)
Mkt Cap $2M
$0.14
$2.18
52-Week Range
At a Glance
AI-generatedAzitra, Inc.
8-K
Azitra, Inc. entered a Securities Purchase Agreement on March 18, 2026, issuing 10,485 shares of Series A convertible non-redeemable preferred stock at $1,000 each, plus Series B and C warrants to purchase up to 85,233,126 shares of common stock each at $0.123 exercise price, in a PIPE Financing closing March 20, 2026, for initial $10.5 million proceeds, potentially $31.4 million total. Funds support R&D, corporate expenses, and working capital.$2M
Market Cap
—
Revenue
—
Net Income
Employees12
Fundamentals
How The Business Makes Money
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001701478
ISINUS05479L3024
CUSIP05479L203
Phone203 646 6446
Address21 Business Park Drive, Branford, CT, 06405, US
SEC EDGAR